The Truth About Psychedelics

THE TRUTH ABOUT PSYCHEDELICS - A Live Drug Science Podcast Recording Wednesday 13 November 2019, 19:00 | FEST - Camden Stables Market, London NW1 8AH

<1>In this first EVER live Drug Science podcast recording, Professor Nutt invites you to join him in an evening of psychedelic discussion.

The world is entering a new phase of psychiatric treatments. Traditional pharmacology is currently unable to address the decline of mental health and wellbeing. Professor Nutt has assembled some of the best and brightest minds in psychedelic science and wellbeing to address the question- Do Psychedelics have a role to play in mental health and wellbeing? Drug Science will address depression, ecological collapse, microdosing and much more.

Speakers to include:

Prof David Nutt

Edmond J Safra chair in Neuropsychopharmacology at Imperial College London and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences there. Prof Nutt was a member of the Committee on Safety of Medicine, and was President of the European College of Neuropsychopharmacology.

Michelle Baker Jones

Michelle is an integrative psycho-therapeutic counsellor. She is a member of the Imperial Colleges Psychedelic Research Team exploring the therapeutic potential of psilocybin. She also offers individual integration sessions for people who are struggling to process Psychedelic experiences.

Special Guest – Matt Jackson

A participant from the Psilocybin for Treatment-Resistant Depression study.

Dr Sam Gandy

Sam has a PhD in Ecological Science from the University of Aberdeen and a Masters in Entomology from Imperial College London. His research has focused on how psychedelics could save the planet from ecological collapse by remedying our disconnection from nature.

Dr David Erritzøe

At Imperial College London, Dr Erritzøe is conducting research in neurobiology and the treatment potential of MDMA/psilocybin and LSD. He is also leading ground-breaking trials into microdosing LSD, asking the all-important question, is microdosing real or placebo?

After the psychotherapy and medical treatment phases in the last century, we are at the start of the phase where we use drugs to assist and empower psychotherapeutic processes. The origins of this exciting new development are the massive growth of neuropsychopharmacology, particularly in relation to the use of psychedelics (e.g. LSD, Psilocybin) and entactogens (e.g. MDMA). New research on the impact of these drugs on brain functions shows clear impacts on brain processes that contribute to maladaptive behavioural processes. Parallel research has shown efficacy for psilocybin and MDMA in disorders such as resistant depression and PTSD.

To access the event click on the link below

www.eventbrite.co.uk

Progress - National Consortium of Consultant Nurses in Dual Diagnosis & Substance Use